Marcia Frellick

Results from the PEARL-II study show treatment-experienced patients with hepatitis C genotype 1b achieved SVR rates of greater than 96% when treated with a combination of ABT 450 with ritonavir, co-formulated with ombitasvir and dasabuvir, without the need for ribavirin.

Patients with celiac disease treated with larazotide acetate experienced improvements in GI symptoms and non-GI symptoms such as headache and fatigue, as well as significant reductions in the number of symptomatic days.

Patients with IBS-D in two phase II trials of eluxadoline experienced sustained improvements in abdominal pain and bowel symptoms at 26 weeks of treatment, with mild side effects.

Fecal microbiota transplants appear safe and patients tolerate them well in trials, but the evidence isn't there yet to establish overall benefit for treating ulcerative colitis.

An all-oral, ribavirin-free, interferon-free combination of three direct-acting antiviral agents that had achieved sustained virologic response in 92% of patients with chronic HCV genotype 1 infection has demonstrated even greater response in patients with genotype 4 infection.

Treatment with an 8-week regimen of combination sofosbuvir plus ledipasvir with or without ribavirin produced sustained virologic response rates (SVR) similar to those achieved with a 12-week regimen in non-cirrhotic, previously untreated, genotype 1 hepatitis C patients, according to results from the ION-3 trial.

Patients in the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial who were also treated with statins experienced a significant decrease in time to histological disease progression compared to patients who did not receive statin treatment.

Within the next two years, treatments for hepatitis C with 95% cure rates that are all-oral, interferon-free, and effective within 12 weeks or less with negligible side effects will be readily available.

Phase 2 study results show patients with ulcerative colitis treated with an investigational oral compound achieved higher rates of remission, reduced rectal bleeding, and increased mucosal healing compared to patients who received placebo.

Retrospective analysis reveals that statin use is not associated with increased risk of cancer.

Post-traumatic stress disorder more than doubles a veteran's risk of death from any cause and is an independent risk factor for cardiovascular disease.

Poor medication plan adherence poses major health risks in patients with cardiovascular illnesses. Better adherence starts with better communication.

Study shows that cholesteryl ester transfer protein (CETP) inhibitor anacetrapib reduced LDL by 40% and doubled HDL in patients with coronary disease.

GRAVITAS trial results show that high-dose clopidogrel does not reduce the incidence of death, heart attack, or blood clots in high-risk patients.

Once you've determined that a patient truly is statin-intolerant, there are several viable alternatives for lipid-lowering therapy, including niacin.

Intravenous treatment with the iron compound ferric carboxymaltose improves health-related quality of life in patients with chronic heart failure.

Unique treatment using fat-derived stem cells reduced heart tissue damage and improved cardiac blood flow in patients who had suffered a heart attack.

Alternate statin-dosing protocol shows significant reductions in LDL and total cholesterol in previously statin-intolerant women.

MESA trial finds association between lower coronary artery calcium and carotid artery thickness and adherence to AHA "Life's Simple 7" health factors.